Calcium Delivery by Electroporation Induces In Vitro Cell Death through Mitochondrial Dysfunction without DNA Damages.
calcium electroporation
electrochemotherapy
genotoxicity
magnesium
mitochondria
spheroids
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
12 Feb 2020
12 Feb 2020
Historique:
received:
21
01
2020
accepted:
06
02
2020
entrez:
16
2
2020
pubmed:
16
2
2020
medline:
16
2
2020
Statut:
epublish
Résumé
Adolescent cancer survivors present increased risks of developing secondary malignancies due to cancer therapy. Electrochemotherapy is a promising anti-cancer approach that potentiates the cytotoxic effect of drugs by application of external electric field pulses. Clinicians proposed to associate electroporation and calcium. The current study aims to unravel the toxic mechanisms of calcium electroporation, in particular if calcium presents a genotoxic profile and if its cytotoxicity comes from the ion itself or from osmotic stress. Human dermal fibroblasts and colorectal HCT-116 cell line were treated by electrochemotherapy using bleomycin, cisplatin, calcium, or magnesium. Genotoxicity, cytotoxicity, mitochondrial membrane potential, ATP content, and caspases activities were assessed in cells grown on monolayers and tumor growth was assayed in tumor spheroids. Results in monolayers show that unlike cisplatin and bleomycin, calcium electroporation induces cell death without genotoxicity induction. Its cytotoxicity correlates with a dramatic fall in mitochondrial membrane potential and ATP depletion. Opposite of magnesium, over seven days of calcium electroporation led to spheroid tumor growth regression. As non-genotoxic, calcium has a better safety profile than conventional anticancer drugs. Calcium is already authorized by different health authorities worldwide. Therefore, calcium electroporation should be a cancer treatment of choice due to the reduced potential of secondary malignancies.
Identifiants
pubmed: 32059457
pii: cancers12020425
doi: 10.3390/cancers12020425
pmc: PMC7072520
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : SILAB-Jean Paufique foundation (LG) and NUMEP Plan Cancer PC201615 grant (MPR)
ID : PC201615
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest. The funding body did not play any role in the design of the study and collection, analyses, and interpretation of data and in writing the manuscript.
Références
Nat Rev Cancer. 2008 Dec;8(12):957-67
pubmed: 19005492
Cancer Res. 2017 Aug 15;77(16):4389-4401
pubmed: 28760856
Biomaterials. 2012 Apr;33(10):3036-46
pubmed: 22244695
Oncotarget. 2018 Jan 30;9(14):11604-11618
pubmed: 29545923
Biochim Biophys Acta. 2014 Mar;1840(3):1204-8
pubmed: 24342489
Acta Oncol. 2018 Mar;57(3):311-319
pubmed: 28816072
Cancer Res. 2012 Mar 15;72(6):1336-41
pubmed: 22282658
Laryngoscope Investig Otolaryngol. 2019 Jan 03;4(1):49-56
pubmed: 30828619
Nat Rev Mol Cell Biol. 2003 Jul;4(7):517-29
pubmed: 12838335
Br J Cancer. 2001 May 4;84(9):1272-9
pubmed: 11336481
J Biomol Screen. 2014 Oct;19(9):1246-54
pubmed: 24980598
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818780088
pubmed: 29879868
Cancer. 2016 Oct;122(19):3075-86
pubmed: 27377470
Med Clin North Am. 2017 Nov;101(6):1167-1180
pubmed: 28992861
Cancer Res. 1993 Nov 15;53(22):5462-9
pubmed: 7693342
Biochem Pharmacol. 1988 Dec 15;37(24):4727-33
pubmed: 2462423
Anticancer Drugs. 2004 Jul;15(6):593-7
pubmed: 15205602
Toxicol Lett. 2018 May 1;287:100-107
pubmed: 29421331
Met Ions Life Sci. 2013;12:119-68
pubmed: 23595672
Mutagenesis. 2016 Jan;31(1):43-50
pubmed: 26282955
Biochem Biophys Res Commun. 1993 Jul 15;194(1):333-7
pubmed: 7687434
Eur J Dermatol. 2018 Jun 1;28(3):287-313
pubmed: 30105989
PLoS One. 2015 Dec 03;10(12):e0144028
pubmed: 26633834
Arch Toxicol. 2019 Aug;93(8):2103-2114
pubmed: 31289893
Arch Toxicol. 2016 Aug;90(8):1983-95
pubmed: 26404763
Sci Rep. 2018 Jun 20;8(1):9412
pubmed: 29925935
Acta Oncol. 2018 Jul;57(7):874-882
pubmed: 29577784
Environ Mol Mutagen. 2014 Aug;55(7):542-55
pubmed: 24756928
Drug Deliv. 2018 Nov;25(1):1766-1778
pubmed: 30311803
Biomaterials. 2016 Feb;78:129-39
pubmed: 26694987
J Membr Biol. 2013 Oct;246(10):745-50
pubmed: 23519620
J Membr Biol. 1972 Dec 29;10(3):279-90
pubmed: 4667921
PLoS One. 2015 May 07;10(5):e0128034
pubmed: 25950928
Oncotarget. 2017 Apr 4;8(14):23996-24008
pubmed: 28177918
Oncoimmunology. 2017 Mar 17;6(5):e1301332
pubmed: 28638724
Anal Biochem. 2018 Jul 1;552:50-59
pubmed: 28711444
Trends Cancer. 2017 Dec;3(12):857-870
pubmed: 29198441
Environ Mol Mutagen. 2013 Dec;54(9):737-46
pubmed: 24105934
Nat Rev Mol Cell Biol. 2007 Oct;8(10):839-45
pubmed: 17684528
PLoS One. 2017 Jul 25;12(7):e0181839
pubmed: 28742810
Annu Rev Biomed Eng. 2014 Jul 11;16:295-320
pubmed: 24905876
Biomed Eng Online. 2014 Mar 12;13(1):29
pubmed: 24621079
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818788077
pubmed: 30012047
Am J Physiol Cell Physiol. 2017 Aug 1;313(2):C146-C153
pubmed: 28515085
Tissue Eng Part A. 2010 Oct;16(10):3199-206
pubmed: 20528673
Mutat Res. 2011 Oct 1;715(1-2):25-31
pubmed: 21824484
J Control Release. 2013 Apr 28;167(2):138-47
pubmed: 23385033